Voleon Capital Management LP Invests $292,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Voleon Capital Management LP purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,266 shares of the company's stock, valued at approximately $292,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Summit Investment Advisors Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after purchasing an additional 244 shares during the last quarter. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $25,000. Bank of New York Mellon Corp raised its stake in Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after buying an additional 498 shares during the period. Swiss National Bank grew its position in Tarsus Pharmaceuticals by 1.2% in the 4th quarter. Swiss National Bank now owns 52,333 shares of the company's stock valued at $2,898,000 after purchasing an additional 600 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Tarsus Pharmaceuticals by 10.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock valued at $449,000 after buying an additional 789 shares during the last quarter. Institutional investors own 90.01% of the company's stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 3,341 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the sale, the insider now owns 50,751 shares of the company's stock, valued at approximately $2,349,263.79. The trade was a 4.36 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,542 shares of company stock worth $1,581,173. Insiders own 8.25% of the company's stock.

Analyst Upgrades and Downgrades

TARS has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research report on Monday. Guggenheim boosted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $66.33.

Tarsus Pharmaceuticals Trading Down 3.4 %

NASDAQ:TARS traded down $1.62 during mid-day trading on Tuesday, reaching $46.38. 331,295 shares of the company's stock traded hands, compared to its average volume of 695,784. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -12.17 and a beta of 0.94. The company has a 50 day moving average price of $48.05 and a 200-day moving average price of $48.98. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.